The Epworth Centre for Immunotherapies and Snowdome Laboratories (ECISL) contribution to national and international clinical data registries in myeloma and lymphoma.

Abstract

Epworth Healthcare contributes to clinical data registries - Myeloma and Related Diseases Registry (MRDR), and Lymphoma and Related Diseases Registry (LARDR) - coordinated by the Molecular Oncology and Cancer Immunology research group. Contribution to clinical data registries is important in general and in particular for our patients diagnosed with myeloma and lymphoma respectively. The aims of the Australian and New Zealand registries are to monitor access to care, benchmark outcomes nationally and internationally, explore variation in practice, process and outcome measures, monitor trends in incidence and survival, explore the factors that influence outcomes including survival and quality of life and act as a resource for clinical research and trials. The MRDR site report also demonstrates that Epworth Freemason’s myeloma patients have a better overall survival trend compared to other sites. Epworth patients with myeloma also demonstrate superior progression-free survival compared to other sites. The LaRDR site report specifies Epworth’s patients with diffuse large B cell lymphoma (DLBCL) having a higher rates of complete response compared to other sites.